GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue

Hims & Hers Health is outpacing GoodRx on revenue growth, with quarterly revenue rising from $278.2 million in Q1 2024 to $617.8 million in Q4 2025, while GoodRx has remained essentially flat around $195 million-$204 million per quarter. GoodRx posted Q1 2026 sales of $194 million, down 4.4% year over year, though its Pharma Direct unit grew 82% and now contributes about 27% of revenue. The article is primarily a comparative business update with mild negative tone on GoodRx and constructive momentum for Hims & Hers.

Analysis

The key signal is not just that one company is growing faster, but that the gap is becoming self-reinforcing. In healthcare consumer platforms, revenue acceleration usually precedes cheaper customer acquisition and better payer/pharma leverage; the loser is forced to spend harder just to defend share. That makes this a market-share narrative more than a simple top-line comparison, with HIMS increasingly acting like the category anchor while GDRX looks like a mature utility with limited pricing power.

The second-order effect is margin structure. HIMS can absorb growth investments because its gross margin base gives it operating leverage, while GDRX’s model looks more exposed to transaction-level commoditization and regulatory friction. If the current pattern persists for another 2-3 quarters, the market will likely start valuing HIMS less like a telehealth growth story and more like a durable consumer subscription platform, while GDRX risks multiple compression despite any isolated product wins.

The biggest contrarian risk is that the market may be overextrapolating HIMS’ recent growth if any of that demand is promotion-driven or tied to a narrow product cycle. For GDRX, the bad setup is not necessarily a dramatic collapse; it is a slow deterioration where flat revenue masks worsening competitive relevance. Near term, the first inflection point to watch is whether HIMS can keep sequential growth intact through the next print without margin leakage, because that will determine if this is a multi-year rerating or just a temporary growth burst.

Key Decisions for Investors

• Go long HIMS vs short GDRX as a 3-6 month pair trade; the cleaner revenue momentum and stronger unit economics should continue to outperform unless HIMS growth materially decelerates.
• If already long HIMS, add on post-earnings confirmation only; use any 5-8% pullback after a strong print as entry, since the market is likely to reward sequential growth visibility more than headline quarterly beats.
• Avoid initiating fresh long GDRX equity here; the risk/reward is skewed toward value traps unless management can show at least two consecutive quarters of positive revenue inflection.
• For options traders, consider a HIMS call spread into the next earnings window to express upside from another sequential growth beat while capping premium outlay; use a 45-90 day tenor.
• If holding GDRX, hedge with a short-dated downside put spread around the next catalyst, since the stock appears vulnerable to another quarter of stagnation and multiple compression.